You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

    SBC: Pulmokine, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with high morbidity and mortality. Signaling through the PDGFR leads to smooth muscle cell proliferation ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Promoting Responsible Drinking: An Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems Inc            Topic: NIAAA

    DESCRIPTION provided by applicant Excessive alcohol use is associated with a range of serious and costly health social and economic consequences at the individual and societal level This program of research serves as a venue by which to produce and test an innovative science based and cost effective means to intervene in a private convenient and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Clinical Development of Non-compressible Hemostatic Agent for High-Volume Hemorrhage

    SBC: BIOMEDICA MANAGEMENT CORP.            Topic: NHLBI

    DESCRIPTION provided by applicant andquot ClotFoam R andquot is a novel adhesive sealant composition and second generation hemostatic agent This biological agent was designed to arrest moderate to severe blood loss arising from intracavitary traumatic injury or intraoperative hemorrhage without compression stitches or staples Control of Intraoperative hemorrhage in laparoscopic surgery whi ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Anion Exchange Resin for Chirality-based Separation of Single-wall Carbon Nanotubes

    SBC: Sepax Technologies, Inc.            Topic: N/A

    Sepax Technologies, Inc. has identified a new type of anoin-exchange resin which separates single-wall carbon nanotubes (SWCNTs) with >80% recovery yield and resolves in a single pass the chiral tubes of (6,5) well from commercial SWCNT starting materials by Chromatography. Improvement and scale up of the targeted resin production will facilitate the separation of chiral nanotubes for the academic ...

    SBIR Phase II 2012 Department of CommerceNational Institute of Standards and Technology
  5. Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems Inc            Topic: NIAAA

    DESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Therapeutic for Liver Fibrosis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the treatment of liver fibrosis include changes in diet, life-style and/or medications to allevate the unde ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Whole-brain fluorescence and brightfield imaging at single-cell level

    SBC: DMetrix, Inc            Topic: NIA

    DESCRIPTION (provided by applicant): The goal of this project is to develop an open and flexible imaging platform capable of rapid, 0.5- 5 m pixel resolution image capture of large-area histology sections (up to 125 mm by 175 mm), in brightfield and by epi-fluorescence optical sectioning. The project involves state-of-the- art instrumentation development coupled with application programming inter ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Locating the Elderly Overseen by Nurses- LEON

    SBC: Q-Track Corporation            Topic: NIA

    DESCRIPTION (provided by applicant): The proposed effort aims to develop a comprehensive wireless tracking and monitoring system for residents of Long Term Care facilities. The commercial product ElderAlertTM extends Q-Track's real-time location system totrack residents, caregivers, and medical assets within a LTC facility. ElderAlertTM directs caregivers to residents who have fallen or have ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Anti-Fibrotic Therapy for Scleroderma/SSc

    SBC: Angion Biomedica Corp.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, blood vessels, GI and kidney. Many patients who suffer from scleroderma/SSc also have a loss of pulmonary function. Scleroderma/SSc affects approximately 400,000 to 900,000 people in th ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. A NOVEL MICROFLUIDIC DEVICE FOR SELECTION AND OPTIMIZATION OF DRUG DELIVERY VEHIC

    SBC: CFD Research Corporation            Topic: NCI

    DESCRIPTION (provided by applicant): We propose to develop and demonstrate a novel microfluidic device and assay for selection and optimization of delivery vehicles, specifically non-viral vectors for drug delivery to tumors. Tumor drug delivery is a complex phenomenon affected by several elements in addition to drug or delivery vehicle's physico-chemical properties. A key factor is tumor mic ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government